Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Viral and Genomic Drivers of Squamous Cell Neoplasms Arising in the Lacrimal Drainage System

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. miRNA Expression in Ovarian Cancer in Fresh Frozen, Formalin-fixed Paraffin-embedded and Plasma Samples

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Use of antidepressants and endometrial-cancer risk: a nationwide nested case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Christoph Wohlmuth
  • Vladimir Djedovic
  • Susanne K Kjaer
  • Allan Jensen
  • Rosalind Glasspool
  • Patricia Roxburgh
  • Anna DeFazio
  • Sharon E Johnatty
  • Penelope M Webb
  • Francesmary Modugno
  • Diether Lambrechts
  • Joellen M Schildkraut
  • Andrew Berchuck
  • Liv Cecilie Vestrheim Thomsen
  • Line Bjorge
  • Estrid Høgdall
  • Claus K Høgdall
  • Ellen L Goode
  • Stacey J Winham
  • Keitaro Matsuo
  • Beth Y Karlan
  • Jenny Lester
  • Marc T Goodman
  • Pamela J Thompson
  • Tanja Pejovic
  • Marjorie J Riggan
  • Katherine Lajkosz
  • Alicia Tone
  • Taymaa May
Vis graf over relationer

OBJECTIVE: Studies on low-grade serous ovarian cancer (LGSC) are limited by a low number of cases. The aim of this study was to define the prognostic significance of age, stage, and CA-125 levels on survival in a multi-institutional cohort of women with pathologically confirmed LGSC.

METHODS: Women with LGSC were identified from the collaborative Ovarian Cancer Association Consortium (OCAC). Cases of newly diagnosed primary LGSC were included if peri-operative CA-125 levels were available. Age at diagnosis, FIGO stage, pre- and post-treatment CA-125 levels, residual disease, adjuvant chemotherapy, disease recurrence, and vital status were collected by the participating institutions. Progression-free (PFS) and overall survival (OS) were calculated. Multivariable (MVA) Cox proportional hazard models were used and hazard ratios (HR) calculated.

RESULTS: A total of 176 women with LGSC were included in this study; 82% had stage III/IV disease. The median PFS was 2.3 years and the median OS was 6.4 years. Age at diagnosis was not significantly associated with worse PFS (p = 0.23) or OS (p = 0.3) (HR per year: 0.99; 95%CI, 0.96-1.01 and 0.98; 95%CI 0.95-1.01). FIGO stage III/IV was independently associated with PFS (HR 4.26, 95%CI 1.43-12.73) and OS (HR 1.69, 95%CI 0.56-5.05). Elevated CA-125 (≥35 U/mL) at diagnosis was not significantly associated with worse PFS (p = 0.87) or OS (p = 0.78) in MVA. Elevated CA-125 (≥35 U/mL) after completion of primary treatment was independently associated with worse PFS (HR 2.81, 95%CI 1.36-5.81) and OS (HR 6.62, 95%CI 2.45-17.92). In the MVA, residual disease was independently associated with PFS (0.022), but not OS (0.85).

CONCLUSION: Advanced LGSC was associated with poor long-term prognosis. FIGO stage and abnormal post-treatment CA-125 level are key prognostic factors inversely associated with PFS and OS.

HIGHLIGHTS: 1. Through a multi-center collaborative effort, data from 176 women with low-grade serous ovarian cancer were analyzed. 2. Although low-grade serous ovarian cancer is often considered indolent, the progression-free and overall survival are poor. 3. Elevated post-treatment CA-125 levels are independently associated with poor survival.

OriginalsprogEngelsk
Artikelnummer1954
TidsskriftCancers
Vol/bind14
Udgave nummer8
ISSN2072-6694
DOI
StatusUdgivet - 13 apr. 2022

ID: 78008439